Gilead and PAHO Announce Milestone Partnership to Accelerate Access to Twice-Yearly Lenacapavir for HIV Prevention Across Latin America and the Caribbean

Go back to Gilead and PAHO Announce Milestone Partnership to Accelerate Access to Twice-Yearly Lenacapavir for HIV Prevention Across Latin America and the Caribbean
Gilead Sciences (NASDAQ: GILD) Delayed: 153.20 -3.31 (2.11%)
Previous Close $156.51    52 Week High $108.63 
Open $154.73    52 Week Low $71.39 
Day High $155.42    P/E 84.64 
Day Low $151.71    EPS $1.81 
Volume 3,207,335